Appointment dossier — Fallopian Tube Cancer

Compounds studied in Fallopian Tube Cancer

• Bevacizumab — Human evidence · 2 positive · PMID 38872480, 22529265
• Olaparib — Human evidence · 2 positive · PMID 37592269, 33743851
• Relacorilant — Human evidence · 2 positive / 1 negative-mixed · PMID 42334771, 40473448, 39032926, 37364223
• Mirvetuximab Soravtansine — Human evidence · 0 positive / 1 negative-mixed · PMID 30379722
• Nivolumab †Rx — Human evidence · 0 positive · PMID 34593565
• Rucaparib — Human evidence · 0 positive · PMID 34593565
• Carboplatin — Review evidence · 1 positive · PMID 37592269
• Fuzuloparib — Review evidence · 1 positive · PMID 34118019
• Paclitaxel — Review evidence · 1 positive · PMID 37592269

“Positive” means a study reported a positive result — most are early lab/animal work that may not translate to people.

Open recruiting trials (18)

• NCT06161025 · Phase 2 / Phase 3 — A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (United States)
• NCT06994195 · Phase 3 — A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01) (China)
• NCT07023484 · Phase 2 — Personalized Timing of Interval Debulking Surgery in Advanced Ovarian Cancer (China)
• NCT05867251 · Phase 1 / Phase 2 — Study of AVZO-021 in Patients With Advanced Solid Tumors (United States)
• NCT05579366 · Phase 1 / Phase 2 — Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) (United States)
• NCT06690775 · Phase 2 — CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer. (United States)
• NCT05985655 · Phase 1 / Phase 2 — Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors (United States)
• NCT07489287 · Phase 1 — GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer (United States)
• NCT05092373 · Phase 1 — Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax (United States)
• NCT06469281 · Phase 1 — A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers (United States)
• NCT06024109 — Performance of SYMMCORA® vs. V-Loc® Suture Material in Patients Undergoing Laparoscopic Total Hysterectomy (Germany)
• NCT00005095 — Specimen and Data Study for Ovarian Cancer Early Detection and Prevention (United States)
• NCT05912972 — Development and Management of Registry in Patients With Gynecologic Cancer in Korea (South Korea)
• NCT06730347 · Phase 2 — A Study of Lorigerlimab in Participants With Advanced Solid Tumors (United States)
• NCT04196257 · Phase 1 — BP1001-A in Patients With Advanced or Recurrent Solid Tumors (United States)
• NCT06580314 · Phase 3 — Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer (United States)
• NCT04520074 · Phase 3 — Adjuvant Chemotherapy of Three-step Regimen in BRCA1/2 Wide Type Ovarian Cancer (ACTS-2) (China)
• NCT06504147 · Phase 2 — A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery (United States)

Most-relevant first: trials that name Fallopian Tube Cancer, then broader trials you may still qualify for. 116 recruiting trials name this cancer on ClinicalTrials.gov. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.

Interactions & safety to discuss

Not a complete check — a drug not listed here is not therefore safe. Show your pharmacist your full list.

• Nivolumab †Rx × immunosuppressants (high-stakes) — Avoid (high)
• Nivolumab †Rx × Ipilimumab — Synergize (moderate)
• Nivolumab †Rx × corticosteroids — Use For IrAE (low)

Financial help to look into

• PAN Foundation — Copay assistance funds by diagnosis (funds open and close as money allows). https://www.panfoundation.org/
• HealthWell Foundation — Copay and premium assistance funds by disease. https://www.healthwellfoundation.org/
• CancerCare — financial assistance — Limited grants plus free financial counseling. https://www.cancercare.org/financial
• Family Reach — Help with everyday living costs (rent, transport, food) during treatment. https://familyreach.org/
• NeedyMeds — Searchable directory of drug patient-assistance and discount programs. https://www.needymeds.org/

For each medicine above, search manufacturer and nonprofit programs at medicineassistancetool.org.

Questions to ask your oncologist

1. I've read that Bevacizumab has been studied in people for Fallopian Tube Cancer — what's the evidence, and is it an option or available in a trial for me?
2. I've read that Olaparib has been studied in people for Fallopian Tube Cancer — what's the evidence, and is it an option or available in a trial for me?
3. I've read that Relacorilant has been studied in people for Fallopian Tube Cancer — what's the evidence, and is it an option or available in a trial for me?
4. Of the open trials I found (for example NCT06161025), am I eligible for any — here or at a larger cancer center?
5. What is my exact diagnosis — the type, subtype, stage, and grade?
6. Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
7. Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
8. What is the goal of treatment for me — cure, long-term control, or comfort?
9. What are all of my standard treatment options, and what does each one involve?
10. What is the realistic benefit of each option, in actual numbers?
11. What are the most common and the most serious side effects, and how are they managed?
12. How will we know if treatment is working, and how often will I be scanned or tested?
13. If the first treatment doesn't work, what are the next options?
14. Are there gentler options if I want to prioritize quality of life?
15. Am I eligible for any clinical trials — here or at a larger/academic cancer center?
16. Is my case reviewed by a multidisciplinary tumor board?
17. Would a second opinion at a center that treats my cancer often be worthwhile?
18. Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
19. Which symptoms are emergencies, and who do I call after hours?
20. Should I see palliative or supportive care alongside my treatment?
21. How will treatment affect my daily life, work, and (if it matters to me) fertility?
22. What can I safely do myself — diet and activity — and is anything I'm taking risky?